Transcranial Magnetic Stimulation (TMS)

Guideline Number: BHCDG852014

Product:

2001 Generic UnitedHealthcare COC/SPD
2007 Generic UnitedHealthcare COC/SPD
2009 Generic UnitedHealthcare COC/SPD
Product:
2011 Generic UnitedHealthcare COC/SPD

Effective Date: February, 2014
Revised Date: Table of Contents:

Instructions for Use 1
Key Points 2
Part I: Benefits, Limitations & Exclusions 2
Part II: Coverage Criteria 4
Part III: Clinical Best Practice 9
Part IV: Additional Resources 10
Part V: Definitions 11
Part VI: References 12
Part VII: Coding 13
Part VIII: History 14

Related Coverage Determination Guidelines:
Major Depressive Disorder

Related Medical Policies:
Optum Clinical Technology Assessment, NeuroStar Transcranial Magnetic Stimulation, 2013
Optum Clinical Technology Assessment, Brainsway Deep Transcranial Magnetic Stimulation, 2013

INSTRUCTIONS FOR USE

This Coverage Determination Guideline provides assistance in interpreting behavioral health benefit plans that are managed by Optum. This Coverage Determination Guideline is also applicable to behavioral health benefit plans managed by Pacificare Behavioral Health and U.S. Behavioral Health Plan, California (doing business as Optum California (“Optum-CA”).

When deciding coverage, the enrollee specific document must be referenced. The terms of an enrollee’s document (e.g., Certificates of Coverage (COCs), Schedules of Benefits (SOBs), or Summary Plan Descriptions (SPDs) may differ greatly from the standard benefit plans upon which this guideline is based.

In the event that the requested service or procedure is limited or excluded from the benefit, is defined differently, or there is otherwise a conflict between this document and the COC/SPD, the enrollee’s specific benefit document supersedes these guidelines.

All reviewers must first identify enrollee eligibility, any federal or state regulatory requirements that supersede the COC/SPD and the plan benefit coverage prior to use of this guideline. Other coverage determination guidelines and clinical guideline may apply.

Optum reserves the right, in its sole discretion, to modify its coverage determination guidelines and clinical guidelines as necessary.

While this Coverage Determination Guideline does reflect Optum’s understanding of current best practices in care, it does not constitute medical advice.
Key Points

- Transcranial Magnetic Stimulation (TMS) is a non-invasive technique used to apply brief magnetic pulses to the brain. The pulses are administered by passing high currents through an electromagnetic coil placed adjacent to the patient’s scalp. The pulses induce an electrical field in the brain tissue activating neurons in the targeted brain structure. By stimulating areas of the brain, the goal is to lessen the duration or severity of depressive episodes (as cited in Optum Technology Assessment, Brainsway, 2013).

- The FDA has approved the NeuroStar TMS Therapy System and the Brainsway Deep TMS System for the treatment of Major Depressive Disorder. Significant differences between the two devices are (as cited in Optum Technology Assessment, Brainsway, 2013):
  - Brainsway Deep TMS enables activation of deep brain regions.
  - The pulse sequence parameters administered during treatment vary.

- TMS is considered an Emerging treatment, and is typically excluded from coverage. This Coverage Determination Guideline is applicable to benefit plans that provide coverage of TMS.

- For benefit plans that provide coverage of TMS, coverage is guided by the criteria in Part II.

- Services should be consistent with evidence-based practice as described in Part III, and should be of sufficient intensity to address the member’s needs (UnitedHealthcare, Certificate of Coverage, 2007, 2009 & 2011).
  - TMS is not considered a first-line intervention for the treatment of Major Depressive Disorder. First-line interventions should be consistent with evidenced-based practices as outlined in the Coverage Determination Guideline for the Treatment of Major Depressive Disorder.

PART I: BENEFITS

Before using this guideline, please check enrollee’s specific plan document and any federal or state mandates, if applicable.

Benefits

Benefits include the following services:

- Diagnostic evaluation and assessment
- Treatment planning
- Referral services
- Medication management
- Member, family, therapeutic group and provider-based case management services
- Crisis intervention

Covered Services

Transcranial Magnetic Stimulation (TMS)
**Covered Health Service(s) – 2001**

Those health services provided for the purpose of preventing, diagnosing or treating a sickness, injury, mental illness, substance abuse, or their symptoms.

A Covered Health Service is a health care service or supply described in Section 1: What’s Covered--Benefits as a Covered Health Service, which is not excluded under Section 2: What’s Not Covered--Exclusions.

**Covered Health Service(s) – 2007, 2009 and 2011**

Those health services, including services, supplies, or Pharmaceutical Products, which we determine to be all of the following:

- Provided for the purpose of preventing, diagnosing or treating a sickness, injury, mental illness, substance abuse, or their symptoms.
- Consistent with nationally recognized scientific evidence as available, and prevailing medical standards and clinical guidelines as described below.
- Not provided for the convenience of the Covered Person, Physician, facility or any other person.
- Described in this Certificate of Coverage under Section 1: Covered Health Services and in the Schedule of Benefits.
- Not otherwise excluded in this Certificate of Coverage under Section 2: Exclusions and Limitations.

In applying the above definition, "scientific evidence" and "prevailing medical standards" shall have the following meanings:

- "Scientific evidence" means the results of controlled clinical trials or other studies published in peer-reviewed, medical literature generally recognized by the relevant medical specialty community.
- "Prevailing medical standards and clinical guidelines" means nationally recognized professional standards of care including, but not limited to, national consensus statements, nationally recognized clinical guidelines, and national specialty society guidelines.

**Limitations and Exclusions**

The requested service or procedure for the treatment of a mental health condition must be reviewed against the language in the enrollee’s benefit document. When the requested service or procedure is limited or excluded from the enrollee’s benefit document, or is otherwise defined differently, it is the terms of the enrollee’s benefit document that prevails.

**Inconsistent or Inappropriate Services or Supplies – 2001, 2007, 2009 & 2011**

Transcranial Magnetic Stimulation (TMS)
Services or supplies for the diagnosis or treatment of Mental Illness that, in the reasonable judgment of the Mental Health/Substance Use Disorder Designee, are any of the following:

- Not consistent with generally accepted standards of medical practice for the treatment of such conditions.
- Not consistent with services backed by credible research soundly demonstrating that the services or supplies will have a measurable and beneficial health outcome, and are therefore considered experimental.
- Not consistent with the level of care guidelines or best practice guidelines as modified from time to time.
- Not clinically appropriate for the member’s Mental Illness or condition based on generally accepted standards of medical practice and benchmarks.

**Promising but Unproven Services - 2011**

Promising but Unproven Services (a.k.a., Emerging) are services that, while unproven and typically not covered, have been studied by a Randomized Control Trial (RCT), well conducted cohort study, or presentation of a case series, whose results have been accepted in abstract form by a major national specialty society for presentation at a society meeting, or has been published or accepted for publication in a peer-reviewed journal. In order to be considered to have “significant potential as an effective treatment,” it must be established that the proposed treatment is likely to produce functional improvement rather than solely an improvement.

**Additional Information**

The lack of a specific exclusion for a service does not imply that the service is covered. The following are examples of conditions or contraindications that are inconsistent with the evidence-base for the implementation of TMS (not an all-inclusive list):

- Services that deviate from the coverage criteria summarized in this document.

TMS is considered an Emerging treatment and is typically excluded from coverage. This Coverage Determination Guideline is applicable to benefit plans that provide coverage of TMS.

**PART II: COVERAGE CRITERIA**

The following coverage criteria are divided into two sections according to the type of TMS device (*NeuroStar* or *Brainsway*) to be used for the treatment of Major Depressive Disorder.
TMS is performed by or under the supervision of a board certified licensed psychiatrist trained in the use of the applicable TMS device according to requirements outlined by the system user manuals.

The criteria outlined in this guideline are consistent with the most current evidence and recommended indications for use according to Optum’s most recent Technology Assessments approved by the Clinical Technology Assessment Committee.

**Criteria for Initial Treatment**

As part of meeting the below coverage criteria, the provider must specify the device being used for TMS treatment.

**NeuroStar (TMS) Therapy**

- *NeuroStar (TMS) Therapy* may be indicated when all of the following criteria are met:
  - The member is 22-70 years old; and
  - The member has been diagnosed with Major Depressive Disorder; and
  - The member’s condition has not responded to between 1 and 3 prior antidepressant medication trials at or above the minimal effective dose and duration in the current episode following algorithm driven treatment as defined by either Sequenced Treatment Alternatives to Relieve Depression (STAR*D) or the Texas Medication Algorithms Project (TMAP); and
  - The member’s condition has not responded to more than 3 lifetime antidepressant trials of adequate dose and duration following algorithm driven treatment as defined by (STAR*D) or (TMAP).
  - The member’s current baseline depression measurement score has been documented according to one of the following validated rating scales:
    - Beck Depression Scale (BDI),
    - Hamilton Depression Rating Scale (HDRS),
    - Montgomery-Asberg Depression Rating Scale (MADRS) or
    - Patient Health Questionnaire (PHQ-9)

- The safety and effectiveness of *NeuroStar (TMS) Therapy* have not been established for members who:
  - Have not received antidepressant therapy
- Are suicidal or have a history of suicide
- Have a history of a Substance-Related Disorder, Obsessive Compulsive Disorder, or Posttraumatic Stress Disorder
- Are diagnosed with Schizophrenia, another Psychotic Disorder, Bipolar Disorder, or Major Depressive Disorder with Psychotic Features
- Are diagnosed with a neurological condition including epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, history of repetitive or severe head trauma, or primary/secondary tumors in the Central Nervous System
- Are diagnosed with Major Depressive Disorder but who have not benefitted from ECT or Vagus Nerve Stimulation (VNS)
- Have metal in or around the head, (e.g., a metal plate, aneurysm coil, cochlear implant, ocular implant, deep brain stimulation device, or stent)
- Have a vagus nerve stimulator or implant controlled by physiologic signals (e.g., a pacemaker, implantable cardioverter defibrillator)
- Are pregnant or nursing.
- Additionally providers should be alert to signs of an imminent seizure and terminate the treatment session if those signs appear. Patients at potential increased risk of seizure include those who:
  - Are concurrently taking medications such as tricyclic antidepressants, neuroleptic medications, or other drugs that are known to lower the threshold for seizures.
  - Have a secondary condition that may significantly alter electrolyte balance or lower seizure threshold

- If the initial coverage criteria are met, 10-15 sessions over a 4 week maximum period will be authorized after a review of the initial treatment plan. At the end of the 4 week period, criteria for continued treatment will be applied.

**Brainsway DTMS**

- *Brainsway DTMS* may be indicated when all of the following criteria are met:
  - The member is 22-68 years old; and
o The member has been diagnosed with Major Depressive Disorder; and

o The duration of the current episode is at least one month but no more than seven years; and

o The member’s condition has not responded to at least one but no more than four antidepressant treatments in the current episode, or has not tolerated two antidepressant medications at or above the minimal effective dose and duration in the current episode following algorithm driven treatment as defined by either (STAR*D) or (TMAP).

o The member’s current baseline depression measurement score has been documented according to one of the following validated rating scales:
  - Beck Depression Scale (BDI),
  - Hamilton Depression Rating Scale (HDRS),
  - Montgomery-Asberg Depression Rating Scale (MADRS)
  - Patient Health Questionnaire (PHQ-9)

- The safety and effectiveness of Brainsway DTMS have not been established for members who:
  o Have not received antidepressant therapy
  o Are suicidal or have a history of suicide
  o Have a history of a Schizophrenia or another Psychotic Disorder, Bipolar Disorder, Obsessive Compulsive Disorder, Posttraumatic Stress Disorder, or an Eating Disorder
  o Are diagnosed with a primary Anxiety Disorder or Personality Disorder
  o Are diagnosed with a neurological disorder including conditions that heighten the risk of seizure
  o Are diagnosed with Major Depressive Disorder but who have not benefitted from ECT, Vagus Nerve Stimulation (VNS), Repetitive Transcranial Magnetic Stimulation (rTMS), or Deep Brain Stimulation
  o Have metal in or around the head, (e.g., a metal plate, aneurysm coil, cochlear implant, ocular implant, deep brain stimulation device, or stent)
  o Are pregnant or nursing
• If the initial coverage criteria are met, 10-15 sessions over a 4 week maximum period will be authorized after a review of the initial treatment plan. At end of the 4 week period, criteria for continued treatment will be applied.

Criteria for Continued Treatment

• After the initial treatment sessions have been completed, a concurrent review will be conducted to review the member’s response to treatment.
  o Adequate treatment response after 10-15 sessions is typically considered at least 50% improvement from the member’s baseline depression score (Avery, 2008).

• Providers should document weekly measurement scores of the member’s depressive symptoms as evidence of the member’s response at the beginning of each treatment week, with at least but no more than 5 business days between measurement periods.

• If there has been a less than 50% improvement of symptoms after the initial 10-15 sessions have been completed, the following may be indicated:
  o A reevaluation of the member’s treatment plan and whether changes to the member’s course of treatment or level of care are required.
  o A reassessment of the member’s motor threshold;
    ▪ If the motor threshold is modified, 5 additional sessions may be authorized to determine response with a concurrent review at the end of the 5 sessions.

• If there has been at least 50% improvement, the remaining sessions may be authorized with weekly measurement of the member’s symptoms and updates to the treatment plan as appropriate.

• After completion of the standard TMS course, it should be determined if remission has been achieved. Remission is typically defined by the following measurement scores (O’Reardon, 2007; McDonald, 2011):
  o Beck Depression Scale (BDI) score of <9
  o Hamilton Depression Rating Scale (HAM-D) score of <8 on the HAM-D-17 and <11 on the HAM-D-24
  o Montgomery-Asberg Depression Rating Scale (MADRS) score of < 10
  o Patient Health Questionnaire (PHQ-9) score of < 5
If remission has been achieved, the provider should initiate taper sessions.

If the member has not adequately achieved remission, further review and modifications to the treatment plan are required.

**PART III: CLINICAL BEST PRACTICE**

**Evaluation**

An evaluation is conducted to identify the events which triggered the request for service at this particular point (i.e., the “Why Now”) (Optum Level of Care Guidelines, 2014). All of the following should be evaluated as part of the standard evaluation of Major Depressive Disorder (American Psychiatric Association, Clinical Practice Guideline, Major Depressive Disorder, 2010):

- The events leading up to the current episode of care
- Baseline measurement of depressive symptoms with the use of one of the following validated rating scales (O’Reardon, 2007):
  - Beck Depression Scale (BDI),
  - Hamilton Depression Rating Scale (HDRS),
  - Montgomery-Asberg Depression Rating Scale (MADRS) or
  - Patient Health Questionnaire (PHQ-9)
- Current level of functioning
- The identification of any co-occurring conditions
- Current and historic substance use
- History of medication treatment trials and response
- The history of interventions including psychosocial interventions, use of community resources, and response to previous interventions
- Side effects experienced from prescribed and over-the-counter medications
- Results of laboratory tests when indicated
- The history of the onset and progression of symptoms
- The member’s ability to make informed treatment decisions
- The ability of the member’s family/caregiver to participate in the member’s treatment
- The optimal treatment setting and the member’s ability to benefit from a different level of care
Suicide risk should be evaluated. Assessment of suicide risk should include the following (American Psychiatric Association, Clinical Practice Guideline, Suicidal Behaviors, 2003):

- The member's most current diagnoses
- Current suicidal ideation, plan and means
- The history of suicidal behavior
- The nature of the current crisis or other unique issues that may have precipitated suicidal behavior
- Relevant familial factors such as the history of attempts, completion of suicide, and mental illness

In addition to the elements of a standard evaluation, members being considered for TMS should also be evaluated for the specific indications, and safety and effectiveness considerations outlined in Part II.

**Treatment**

- Prior to initiating treatment, the member’s motor threshold (MT) is determined in order to provide an estimate of the magnetic field intensity, and to provide a head surface landmark to permit navigation to the treatment location.
- (MT) should be reestablished each week to ensure the most accurate treatment location.
- At the start of each treatment week a severity of depression measurement with one of the below validated rating scales should be repeated with at least 5 business days between each measurement period.
  - Beck Depression Scale (BDI)
  - Hamilton Depression Rating Scale (HDRS-17 or 21)
  - Montgomery-Asberg Depression Rating Scale (MADRS)
  - Patient Health Questionnaire (PHQ-9)
- At the completion of the standard TMS course, a remission measurement should be administered. Remission is indicated by the following scores (O'Reardon, 2007; McDonald, 2011):
  - Beck Depression Scale (BDI) score of <9
  - Hamilton Depression Rating Scale (HAM-D) score of <8 on the HAM-D-17 and <11 on the HAM-D-24
  - Montgomery-Asberg Depression Rating Scale (MADRS) score of < 10
- Patient Health Questionnaire (PHQ-9) score of < 5
  - If remission has been achieved taper sessions should be initiated as indicated by the member’s treatment plan, typically over 6 sessions (O’Reardon, 2007).
  - If the member has not adequately responded to treatment, further review and reassessment are required.
  - Current evidence does not recommend continuation of TMS treatment beyond 6 weeks once a full course of TMS has been completed (Avery, 2008).

**PART IV: ADDITIONAL RESOURCES**

**Clinical Protocols**
Optum maintains clinical protocols that include the Level of Care Guidelines and Best Practice Guidelines which describe the scientific evidence, prevailing medical standards and clinical guidelines supporting our determinations regarding treatment. These clinical protocols are available to Covered Persons upon request, and to Physicians and other behavioral health care professionals on ubhonline.

**Peer Review**
Optum will offer a peer review to the provider when services do not appear to conform to this guideline. The purpose of a peer review is to allow the provider the opportunity to share additional or new information about the case to assist the Peer Reviewer in making a determination including, when necessary, to clarify a diagnosis.

**Second Opinion Evaluations**
Optum facilitates obtaining a second opinion evaluation when requested by a member, provider, of when Optum otherwise determines that a second opinion is necessary to make a determination, clarify a diagnosis or improve treatment planning and care for the member.

**Referral Assistance**
Optum provides assistance with accessing care when the provider and/or member determine that there is not an appropriate match with the member’s clinical needs and goals, or if additional providers should be involved in delivering treatment.

**PART V: DEFINITIONS**
Diagnostic and Statistical Manual of the American Psychiatric Association (DSM) A manual produced by the American Psychiatric Association which provides the diagnostic criteria for mental health and substance use disorders, and other problems that may be the focus of clinical attention. Unless otherwise noted, the current edition of the DSM applies.

Major Depressive Disorder According to the DSM, Major Depressive Disorder is a form of Mood Disorder whose essential feature is the presence of a Major Depressive episode of at least two weeks duration during which there is either depressed mood or the loss of interest or pleasure in nearly all activities.

Motor Threshold The MT is the minimum intensity required to evoke a response in the target area. The TMS intensity usually will need periodic adjustment according to the subject's MT

Outpatient Visits provided in an ambulatory setting.

Prevailing Medical Standards and Clinical Guidelines Nationally recognized professional standards of care including, but not limited to, national consensus statements, nationally recognized clinical guidelines, and national specialty society guidelines.

PART VI: REFERENCES


PART VII: CODING

The Current Procedural Terminology (CPT) codes and HCPCS codes listed in this guideline are for reference purposes only. Listing of a service code in this guideline does not imply that the service described by this code is a covered or non-covered health service. Coverage is determined by the benefit document.

<table>
<thead>
<tr>
<th>Limited to specific CPT and HCPCS codes?</th>
<th>X Yes □ No</th>
</tr>
</thead>
<tbody>
<tr>
<td>90867</td>
<td>Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management</td>
</tr>
<tr>
<td>90868</td>
<td>Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session</td>
</tr>
<tr>
<td>90869</td>
<td>Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Limited to specific diagnosis codes</th>
<th>X Yes □ No</th>
</tr>
</thead>
<tbody>
<tr>
<td>296.23</td>
<td>Major Depressive Disorder, Single, Severe without Psychotic Features</td>
</tr>
<tr>
<td>296.33</td>
<td>Major Depressive Disorder, Recurrent, Severe without Psychotic Features</td>
</tr>
<tr>
<td>Limited to specific place of service (POS)?</td>
<td>X Yes □ No</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Outpatient</td>
<td></td>
</tr>
<tr>
<td>Limited to specific provider type?</td>
<td>X Yes □ No</td>
</tr>
<tr>
<td>Physician</td>
<td></td>
</tr>
<tr>
<td>Limited to specific revenue codes?</td>
<td>□ Yes X No</td>
</tr>
</tbody>
</table>

**PART VIII: HISTORY**

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Name</th>
<th>Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/2014</td>
<td>L. Urban</td>
<td>Version 1-Final</td>
</tr>
</tbody>
</table>

The enrollee’s specific benefit documents supersede these guidelines and are used to make coverage determinations. These Coverage Determination Guidelines are believed to be current as of the date noted.